College Hill Life Sciences brings together a unique mix of expertise in corporate, financial, marketing and product communications with a dedicated design consultancy. We’ve earned a formidable reputation for creative, comprehensive and effective communications counsel over two decades.
We understand the needs and drivers of the Life Science sector. We’ve been directors, managers, bench scientists, advisors, journalists, editors and accountants - we tailor this industry insight and experience to deliver informed communication and design solutions to showcase your company, product or technology.
We are an international business communications consultancy with bases in Europe, USA and Australia and an international client list. We partner with biotech, pharma, medical device and diagnostic companies, VCs, not for profit organisations and businesses that supply technologies, services and laboratory supplies.
May 24, 2013
BioInvent Recruits Michael Oredsson As New CEO
May 22, 2013
Phagenesis Expands Series B Financing to $17 million
In March College Hill Life Sciences’ ASX-listed client Mesoblast closed AU$170 million (US$176 million) in a private placing with institutional investors. Based on BioWorld’s Insight report issued early March, this is the largest Life Sciences private financing of a public company globally of 2013, just pipping the amounts raised by US-based Ironwood Pharmaceuticals (NASDAQ) and OPKO Health Inc. (NYSE) in January. AIM-listed client, e-Therapeutics, which raised £40 million (US$63m) from an issue of new shares in February, would place it as the fifth largest financing according to figures in the BioWorld report.